Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Graft Vs Host Disease

Graft Vs Host Disease

8

Pipeline Programs↗

9

Active Trials↗

9

Companies Involved↗

Graft Vs Host Disease is an early-stage landscape with 8 programs across 9 companies. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

11/100

Mech. Concentration

14/100

Completion Rate

30/100

Attrition Rate

35/100

Pipeline

Programs by Phase

Preclinical2

Pacritinib

Sobi, Inc.

Etanercept

Immunex

Phase 1

No programs

Phase 24

Methotrexate

Jazz Pharmaceuticals

Tacrolimus

Veloxis Pharmaceuticals

Mycophenolate Mofetil

Roche

Vorinostat

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 32

Cyclophosphamide

Baxter Healthcare Corporation

Ruxolitinib

Incyte

Approved

No programs

Analysis

Modality Breakdown

88%

Small molecule

7 of 8 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

20

clinical trials

Terminated6 · 30%

Active, not recruiting4 · 20%

Recruiting4 · 20%

Completed3 · 15%

Unknown status1 · 5%

Withdrawn1 · 5%

Other1 · 5%

Clinical Trials

Trial Activity

20 trials

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Recruiting·National Cancer Institute (NCI)·Preclinical·NCT05531786·50 enrolled

Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation

Recruiting·CCase Comprehensive Cancer Center·N/A·NCT06649201·40 enrolled

A Randomized Double Blinded Trial of Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

Recruiting·CChildren's Hospital Medical Center, Cincinnati·Phase 2·NCT06450925·190 enrolled

Prospective Multicenter Randomized Study of Ruxolitinib Plus Etanercept vs Ruxolitinib Alone for Corticosteroid-Refractory Severe Acute GVHD After Allogeneic HSCT

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Preclinical·NCT07184853·122 enrolled

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Active, not recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT03842696·43 enrolled

Chronic GVHD Response Measures Validation

Active, not recruiting·FFred Hutchinson Cancer Center·N/A·NCT01902576·383 enrolled

Graft vs Host Disease Prophylaxis in Unrelated Donor Transplantation: a Randomized Clinical Trial Comparing PTCY vs ATG (GRAPPA)

Active, not recruiting·DDKMS gemeinnützige GmbH·Phase 3·NCT05153226·640 enrolled

Development and Psychometric Testing of a Pediatric Chronic Graft- Versus-Host Disease (GVHD) Symptom Scale (PCSS)

Active, not recruiting·National Cancer Institute (NCI)·N/A·NCT04044365·139 enrolled

Use of Bone Marrow-Derived Mesenchymal Stem Cells (Mesencell) for the Treatment of Patients Undergoing Hematopoietic Progenitor Cell Transplantation Who Developed Refractory Moderate or Severe Chronic Graft-versus-Host Disease: A Phase I Clinical Trial

Not yet recruiting·PPontifícia Universidade Católica do Paraná·Phase 1·NCT07826676·20 enrolled

Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT01790568·26 enrolled

Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00775632·78 enrolled

Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease

Completed·—·Phase 3·NCT05663827·6 enrolled

Upfront Ruxolitinib for Chronic Graft-vs-host Disease

Terminated·—·Phase 1·NCT06695507·1 enrolled

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

Terminated·SSandeep Jain, MD·Phase 1/2·NCT02975557·15 enrolled

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00675441·5 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)